Sign up to save your podcasts
Or
Share Cytokinetics' CEO Robert Blum discusses the result of the MAPLE-HCM study of aficamten, and other learnings from the European Society of Cardiology Congress 2025
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Cytokinetics' CEO Robert Blum discusses the result of the MAPLE-HCM study of aficamten, and other learnings from the European Society of Cardiology Congress 2025
He shares what he believes the takeaways are from MAPLE-HCM, which studied aficamten vs a beta blocker in symptomatic obstructive hypertrophic cardiomyopathy patients. Plus, learnings from a competitor's data in non-obstructive HCM, and the status of the company's regulatory review.
View all episodes
By BiotechTV
5
44 ratings
He shares what he believes the takeaways are from MAPLE-HCM, which studied aficamten vs a beta blocker in symptomatic obstructive hypertrophic cardiomyopathy patients. Plus, learnings from a competitor's data in non-obstructive HCM, and the status of the company's regulatory review.
More shows like BiotechTV - News
View all
Planet Money
30,635 Listeners
Odd Lots
1,872 Listeners
a16z Podcast
1,087 Listeners
The Readout Loud
325 Listeners
The Journal.
6,086 Listeners
Biotech 2050 Podcast
60 Listeners
All-In with Chamath, Jason, Sacks Friedberg
9,844 Listeners
Business Of Biotech
86 Listeners
BioCentury This Week
34 Listeners
Biotech Hangout
19 Listeners
ACQ2 by Acquired
260 Listeners
BG2Pod with Brad Gerstner and Bill Gurley
499 Listeners
The Studio at Kendall Square
0 Listeners
Off-Target Effects with Matt Gline
4 Listeners
Biotech CEO Sisterhood
2 Listeners
BioVenture VoiCes with Chris Garabedian
6 Listeners